Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.60
+$0.03 · +0.54%
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Previous close
$5.60
+$0.03 · +0.54%
Regular session · ET · Market data may be delayed.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Day range
Current $5.60
52-week range
Current $5.60
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
53
Fair Value
Sentiment
69
Bullish
Risk
48
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Day range
Current $5.60
52-week range
Current $5.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9.77M USD | 8.33M USD | 15.45M USD | 2.5M USD | — |
| Cost of goods sold | — | — | — | 2.49M USD | — |
| Gross profit | 9.77M USD | 8.33M USD | 15.45M USD | 15K USD | — |
| Research and development | 86.4M USD | 66M USD | 56.78M USD | 91.17M USD | 131.94M USD |
| Selling, general, and administrative | 33.87M USD | 28.95M USD | 30.05M USD | 34.87M USD | 41.32M USD |
| Operating expenses | 120.27M USD | 99.79M USD | 87.89M USD | 126.04M USD | 173.27M USD |
| Interest income | 9.22M USD | 6.94M USD | 3.57M USD | 249K USD | 172K USD |
| Interest expense | 63K USD | 102K USD | 5M USD | 3.8M USD | 1.43M USD |
| Depreciation and amortization | 1.15M USD | 1.25M USD | 1.37M USD | 2.49M USD | 492K USD |
| Operating income | −110.5M USD | −91.46M USD | −72.44M USD | −126.03M USD | −173.27M USD |
| Net income | −109M USD | −89.3M USD | −111.57M USD | −166.01M USD | −174.52M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.00
150.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI53.82M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM35.04M0.04%79.88B USD0.19%$296.01+0.28%
State Street SPDR S&P Biotech ETFXBI33.06M0.29%11.49B USD0.35%$163.81-0.35%
Vanguard Extended Market ETFVXF17.87M0.02%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO12.68M0.09%14.58B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB11.28M0.11%10.72B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO7.89M0.04%17.4B USD0.06%$119.62+0.25%
Schwab U.S. Small-Cap ETFSCHA7.14M0.03%22.56B USD0.03%$34.55+1.01%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
